Analysis Found Rituximab Biosimilar Showed Effectiveness in Treating Pediatric Lupus Nephritis
Rituximab biosimilar BCD020 showed effectiveness in treating lupus nephritis in a pediatric population according to results of a retrospective study published in the journal Biomedicines. A biosimilar is a medication that is as the name suggests very similar to the drug already approved – in this case rituximab. A retrospective study looks back at information […]
ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis
The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis during ACR Convergence 2024. “This is the College’s first lupus nephritis guideline since 2012 and provides evidence-based, expert guidance for the condition in adults and children.” Lupus Therapeutics, clinical affiliate of the […]
Cyclosporine Worked Faster than Mycophenolate Mofetil or Azathioprine for Lupus Nephritis
June 12, 2019 A study presented at EULAR showed that ongoing maintenance therapy with the immunosuppressive drug cyclosporine helped lower proteinuria — the level of protein in urine — faster than other immunosuppressive drugs mycophenolate mofetil or azathioprine in people with lupus nephritis. The three were comparable in their ability to cause remission of Lupus […]
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […]
LRA-Funded Study Pinpoints a Key Player in Lupus Nephritis as Target for New Treatments
October 8, 2020 People with lupus often develop complications in major organs such as the kidneys, called Lupus Nephritis (LN). By taking pictures of the kidneys with a special microscope, Dr. Janos Peti-Peterdi and his team at Keck School of Medicine of University of Southern California (USC) found a chain of molecules that leads to […]
Iguratimod as an Alternative Therapy for Resistant Lupus Nephritis
April 1, 2020 An investigational treatment, iguratimod showed positive results in an early clinical study of people with lupus nephritis that is refractory, meaning it has stubbornly resisted previous treatment with at least two immunosuppressants. Results were reported in Arthritis Research & Therapy. The small study included 14 patients with refractory lupus nephritis. Each were […]
Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis
May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […]
Study Finds Mycophenolate Mofetil Comparable to Standard Treatment for Pediatric Lupus Nephritis
March 19, 2019 A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients. The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, […]
Potential Lupus Nephritis Treatment Works Well with Mycophenolate Acid
November 8, 2019 Aurinia Pharmaceuticals announced results from a study showing that their investigational drug voclosporin did not significantly impact the levels of mychophenolate acid (MPA), the main ingredient in the common standard treatment mycophenolate mofetil (CellCept®) for lupus nephritis. The drug-drug interaction (DDI) study was requested by the Food and Drug Administration to measure […]
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive results as a potential treatment for lupus nephritis in the phase 2 clinical trial NOBILITY. A medicine designed to attach a type of blood cell called B-cells with the marker CD20 on its surface, obinutuzumab […]
LRA-Supported Researchers Developed a Model to Predict Full-Blown Lupus Nephritis Down the Road
A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […]
FDA Accepts Application for Gazyva® as Potential Lupus Nephritis Treatment
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is eager to share exciting news. The U.S. Food and Drug Administration accepted the supplemental Biologics License Application (sBLA) from Genentech for Gazyva® (obinutuzumab) as a potential treatment of lupus nephritis. This development provides hope for another treatment option for those living with lupus […]